Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
- PMID: 16940336
- DOI: 10.7326/0003-4819-145-8-200610170-00139
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
Abstract
Background: Studies from the Spanish influenza era reported that transfusion of influenza-convalescent human blood products reduced mortality in patients with influenza complicated by pneumonia. Treatments for H5N1 influenza are unsatisfactory, and convalescent human plasma containing H5N1 antibodies could be an effective therapy during outbreaks and pandemics.
Purpose: To determine whether transfusion with influenza-convalescent human blood products reduced the risk for death in patients with Spanish influenza pneumonia.
Data sources: Manual search of English-language journals from 1918 to 1925. Citations from retrieved studies were also searched.
Study selection: Published English-language studies that had at least 10 patients in the treatment group, used convalescent blood products to treat Spanish influenza pneumonia in a hospital setting, and reported on a control or comparison group.
Data extraction: Two investigators independently extracted data on study characteristics, outcomes, adverse events, and quality.
Data synthesis: Eight relevant studies involving 1703 patients were found. Treated patients, who were often selected because of more severe illness, were compared with untreated controls with influenza pneumonia in the same hospital or ward. The overall crude case-fatality rate was 16% (54 of 336) among treated patients and 37% (452 of 1219) among controls. The range of absolute risk differences in mortality between the treatment and control groups was 8% to 26% (pooled risk difference, 21% [95% CI, 15% to 27%]). The overall crude case-fatality rate was 19% (28 of 148) among patients who received early treatment (after <4 days of pneumonia complications) and 59% (49 of 83) among patients who received late treatment (after > or =4 days of pneumonia complications). The range of absolute risk differences in mortality between the early treatment group and the late treatment group was 26% to 50% (pooled risk difference, 41% [CI, 29% to 54%]). Adverse effects included chill reactions and possible exacerbations of symptoms in a few patients.
Limitations: Studies were few and had many methodologic limitations. No study was a blinded, randomized, or placebo-controlled trial. Some pertinent studies may have been missed.
Conclusions: Patients with Spanish influenza pneumonia who received influenza-convalescent human blood products may have experienced a clinically important reduction in the risk for death. Convalescent human H5N1 plasma could be an effective, timely, and widely available treatment that should be studied in clinical trials.
Comment in
-
Avian influenza: exploring all the avenues.Ann Intern Med. 2006 Oct 17;145(8):631-2. doi: 10.7326/0003-4819-145-8-200610170-00140. Epub 2006 Aug 29. Ann Intern Med. 2006. PMID: 16940335 No abstract available.
-
Blood products for Spanish influenza: a future H5N1 treatment?Ann Intern Med. 2007 May 1;146(9):686-7; author reply 687. doi: 10.7326/0003-4819-146-9-200705010-00020. Ann Intern Med. 2007. PMID: 17470841 No abstract available.
Similar articles
-
Blood products for Spanish influenza: a future H5N1 treatment?Ann Intern Med. 2007 May 1;146(9):686-7; author reply 687. doi: 10.7326/0003-4819-146-9-200705010-00020. Ann Intern Med. 2007. PMID: 17470841 No abstract available.
-
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.CMAJ. 2020 Jul 6;192(27):E745-E755. doi: 10.1503/cmaj.200642. Epub 2020 May 22. CMAJ. 2020. PMID: 32444482
-
Treatment with convalescent plasma for influenza A (H5N1) infection.N Engl J Med. 2007 Oct 4;357(14):1450-1. doi: 10.1056/NEJMc070359. N Engl J Med. 2007. PMID: 17914053 No abstract available.
-
Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Agency for Healthcare Research and Quality (US). 2018. PMID: 30354042 Free Books & Documents. Review.
-
Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes.Cochrane Database Syst Rev. 2015 Jun 9;(6):CD009982. doi: 10.1002/14651858.CD009982.pub2. Cochrane Database Syst Rev. 2015. PMID: 26059051 Review.
Cited by 167 articles
-
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.Clin Microbiol Infect. 2020 Aug 10:S1198-743X(20)30482-1. doi: 10.1016/j.cmi.2020.08.005. Online ahead of print. Clin Microbiol Infect. 2020. PMID: 32791241 Free PMC article. Review.
-
Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics.Stem Cell Rev Rep. 2020 Aug 13:1-24. doi: 10.1007/s12015-020-10026-5. Online ahead of print. Stem Cell Rev Rep. 2020. PMID: 32789802 Free PMC article. Review.
-
Potential strategies for combating COVID-19.Arch Virol. 2020 Aug 10:1-20. doi: 10.1007/s00705-020-04768-3. Online ahead of print. Arch Virol. 2020. PMID: 32778950 Free PMC article. Review.
-
Natural history of COVID-19 and current knowledge on treatment therapeutic options.Biomed Pharmacother. 2020 Jul 3;129:110493. doi: 10.1016/j.biopha.2020.110493. Online ahead of print. Biomed Pharmacother. 2020. PMID: 32768971 Free PMC article. Review.
-
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.Protein Cell. 2020 Aug 4:1-17. doi: 10.1007/s13238-020-00768-w. Online ahead of print. Protein Cell. 2020. PMID: 32754890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical